{"info": {"address1": "100 Summer Street", "address2": "Suite 2300", "city": "Boston", "state": "MA", "zip": "02110", "country": "United States", "phone": "617 621 7722", "fax": "617 494 0480", "website": "https://ironwoodpharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 253, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas A. McCourt", "age": 67, "title": "CEO & Director", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 1360898, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Minardo", "age": 48, "title": "Senior VP, Chief Legal Officer & Secretary", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 717470, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Shetzline M.D., Ph.D.", "age": 65, "title": "Chief Medical Officer, Senior VP and Head of Research & Drug Development", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 756701, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gregory  Martini", "age": 35, "title": "Senior VP, CFO & Investor Relations", "yearBorn": 1989, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ronald  Silver", "age": 42, "title": "Senior VP, Corporate Controller & Principal Accounting Officer", "yearBorn": 1982, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rosario  Lobrutto M.B.A., M.S., Ph.D.", "title": "VP & Global Head of Technical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tammi  Gaskins", "age": 51, "title": "Senior Vice President & Chief Commercial Officer.", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeff  Ruberti", "title": "Chief Strategy Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 1, "compensationRisk": 1, "shareHolderRightsRisk": 6, "overallRisk": 4, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.13, "open": 3.09, "dayLow": 2.9601, "dayHigh": 3.19, "regularMarketPreviousClose": 3.13, "regularMarketOpen": 3.09, "regularMarketDayLow": 2.96, "regularMarketDayHigh": 3.19, "payoutRatio": 0.0, "beta": 0.257, "trailingPE": 17.277777, "forwardPE": 8.184211, "volume": 2633031, "regularMarketVolume": 2633031, "averageVolume": 1898258, "averageVolume10days": 4983270, "averageDailyVolume10Day": 4983270, "bid": 2.68, "ask": 3.56, "bidSize": 1, "askSize": 1, "marketCap": 505930560, "fiftyTwoWeekLow": 0.53, "fiftyTwoWeekHigh": 5.13, "allTimeHigh": 17.755444, "allTimeLow": 0.53, "priceToSalesTrailing12Months": 1.4924778, "fiftyDayAverage": 1.7046, "twoHundredDayAverage": 1.22975, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 963763584, "profitMargins": 0.08422, "floatShares": 118376371, "sharesOutstanding": 162678647, "sharesShort": 4762545, "sharesShortPriorMonth": 5166794, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.0293, "heldPercentInsiders": 0.02661, "heldPercentInstitutions": 0.92418, "shortRatio": 3.72, "shortPercentOfFloat": 0.044299997, "impliedSharesOutstanding": 162678647, "bookValue": -1.624, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "earningsQuarterlyGrowth": 9.993, "netIncomeToCommon": 28549000, "trailingEps": 0.18, "forwardEps": 0.38, "lastSplitFactor": "1194:1000", "lastSplitDate": 1554163200, "enterpriseToRevenue": 2.843, "enterpriseToEbitda": 6.616, "52WeekChange": -0.11079544, "SandP52WeekChange": 0.1276468, "quoteType": "EQUITY", "currentPrice": 3.11, "targetHighPrice": 3.0, "targetLowPrice": 0.7, "targetMeanPrice": 1.8, "targetMedianPrice": 1.7, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 3, "totalCash": 140407008, "totalCashPerShare": 0.863, "ebitda": 145676000, "totalDebt": 598240000, "quickRatio": 1.075, "currentRatio": 1.129, "totalRevenue": 338987008, "revenuePerShare": 2.103, "returnOnAssets": 0.22875999, "grossProfits": 344192000, "freeCashflow": 39118876, "operatingCashflow": 67683000, "earningsGrowth": 10.468, "revenueGrowth": 0.333, "grossMargins": 1.01535, "ebitdaMargins": 0.42973998, "operatingMargins": 0.63644004, "financialCurrency": "USD", "symbol": "IRWD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1763506302, "regularMarketTime": 1763499602, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1265207400000, "marketState": "PREPRE", "longName": "Ironwood Pharmaceuticals, Inc.", "postMarketChangePercent": -0.4951747, "postMarketPrice": 3.0946, "postMarketChange": -0.015399933, "regularMarketChange": -0.0200002, "regularMarketDayRange": "2.96 - 3.19", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1898258, "fiftyTwoWeekLowChange": 2.58, "fiftyTwoWeekLowChangePercent": 4.8679247, "fiftyTwoWeekRange": "0.53 - 5.13", "fiftyTwoWeekHighChange": -2.0200002, "fiftyTwoWeekHighChangePercent": -0.39376223, "fiftyTwoWeekChangePercent": -11.079544, "earningsTimestamp": 1762781400, "earningsTimestampStart": 1762781400, "earningsTimestampEnd": 1762781400, "earningsCallTimestampStart": 1740663000, "earningsCallTimestampEnd": 1740663000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 0.18, "epsForward": 0.38, "epsCurrentYear": 0.25667, "priceEpsCurrentYear": 12.116725, "fiftyDayAverageChange": 1.4053999, "fiftyDayAverageChangePercent": 0.82447493, "twoHundredDayAverageChange": 1.8802499, "twoHundredDayAverageChangePercent": 1.5289692, "priceToBook": -1.9150246, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "3.0 - Hold", "cryptoTradeable": false, "shortName": "Ironwood Pharmaceuticals, Inc.", "exchange": "NMS", "messageBoardId": "finmb_31498", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -0.638985, "regularMarketPrice": 3.11, "displayName": "Ironwood Pharmaceuticals", "trailingPegRatio": null}, "info_ts": "2025-11-19T06:50:19.770079+00:00"}